Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTATATE + 18F-FDG
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
This is a combination of two radiopharmaceuticals used in positron emission tomography (PET) imaging for neuroendocrine tumors (NETs) and other malignancies. The first component, gallium-68 DOTATATE (NETSPOT), is a somatostatin receptor-targeted PET tracer that binds with high affinity to somatostatin receptor subtype 2 (SSTR2), allowing for the localization of SSTR-positive neuroendocrine tumors. The second component, fluorine-18 fluorodeoxyglucose (FDG), is a glucose analog that accumulates in cells with increased glycolytic activity and is widely used to assess tumor metabolism and aggressiveness. Combined use of these agents provides complementary information on tumor differentiation and metabolic activity—critical for diagnosis, staging, prognosis assessment, and therapy planning in patients with neuroendocrine neoplasms[1][2][6]. NETSPOT was developed as the first FDA-approved kit for preparing Ga-68 DOTATATE[3][5].
- Brand names
- FDG
- Other names
- gallium-68 DOTATATE + fluorine-18 fluorodeoxyglucoseGa-68 DOTATATE + F-18 FDG
02
Targets
GLUT (Glucose transporter family)SSTR2 (Somatostatin receptor type 2)GLUT9 (Glucose transporter type 9)
Beyond the preview
Go deeper on 68Ga-DOTATATE + 18F-FDG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTATATE + 18F-FDG.